Trastuzumab Deruxtecan vs Trastuzumab pamirtecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HER2-Positive Breast Cancer

Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline

Trastuzumab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in HER2-Positive Breast Cancerantibody-drug conjugate
Partial signal

NCT03523585 · Phase 3 · completed

The 608-participant trial was randomized and actively controlled, with progression-free survival assessed by blinded independent central review as the primary clinical endpoint. The primary comparison was statistically significant in favor of trastuzumab deruxtecan, but treatment assignment was open-label rather than double-blinded, supporting a moderate evidence grade.

Next expected readout: January 2027 · NCT06797622 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) (met)

Result source: NCT03523585

Trastuzumab pamirtecan

Developed by BioNTech under a licence from DualityBio Inc.

Phase 3 in HER2-Positive Breast Cancerantibody-drug conjugate
Partial signal

NCT06265428 · Phase 3 · active, not recruiting

Patients were randomly assigned to DB-1303/BNT323 or the active comparator T-DM1 in a Phase 3 trial of about 228 patients, with disease progression (PFS) as the primary measure -- a hard clinical endpoint. However, the study is open-label with no blinding of patients or investigators, and while outside reporting indicates the drug beat T-DM1 on PFS at an interim look, no specific numbers (hazard ratio, medians, or p-value) are available to verify the strength of that result, so this is graded as solid but not top-tier evidence.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT06265428 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Up to approximately 24 months.): NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. (met)

Result source: NCT06265428

Results for HER2-Positive Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Trastuzumab pamirtecan
NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. NCT06265428 · Phase 3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Trastuzumab Deruxtecan

PFS 17.8 months
time to event · months
No placebo or comparator arm
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
16.7 months
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival 39.2 months
time to event · months
No placebo or comparator arm
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
13.3 months
NCT04420598 · Phase 2 · registry result, not featured evidence
ORR 69.7% (n=406)
responder rate · % of participants
No placebo or comparator arm
BICR
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 19.6 months
time to event · months
No placebo or comparator arm
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS-16 12.5% (n=8) @ 16wk
event count · % of participants
No placebo or comparator arm
With PFS at 16 weeks
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
ORR 70% (n=10)
event count · % of participants
No placebo or comparator arm
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 2 more results
55.6% (n=9)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
50% (n=6)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Clinical Benefit 87.5% (n=8)
event count · % of participants
No placebo or comparator arm
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 4 more results
60% (n=10)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
66.7% (n=9)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
50% (n=6)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
71.4% (n=7)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
Available safety results

Trastuzumab Deruxtecan

Dropout rate
76.8%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
62.5%Cohort 1
NCT04420598 · Phase 2 · registry result, not featured evidence
70%Cohort 2
NCT04420598 · Phase 2 · registry result, not featured evidence
88.9%Cohort 3
NCT04420598 · Phase 2 · registry result, not featured evidence
33.3%Cohort 4
NCT04420598 · Phase 2 · registry result, not featured evidence
71.4%Cohort 5
NCT04420598 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
18.2%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
—Cohort 1
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 2
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 3
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 4
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 5
NCT04420598 · Phase 2 · registry result, not featured evidence
Serious AEs
25.5%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
0%Cohort 1
NCT04420598 · Phase 2 · registry result, not featured evidence
10%Cohort 2
NCT04420598 · Phase 2 · registry result, not featured evidence
55.6%Cohort 3
NCT04420598 · Phase 2 · registry result, not featured evidence
16.7%Cohort 4
NCT04420598 · Phase 2 · registry result, not featured evidence
57.1%Cohort 5
NCT04420598 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
nausea 72.3%
alopecia 37.1%
vomiting 37.1%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
fatigue 75%
constipation 62.5%
nausea 50%
NCT04420598 · Phase 2 · registry result, not featured evidence
fatigue 90%
nausea 70%
aspartate aminotransferase increased 50%
NCT04420598 · Phase 2 · registry result, not featured evidence
anaemia 44.4%
fatigue 44.4%
neutropenia 44.4%
NCT04420598 · Phase 2 · registry result, not featured evidence
fatigue 83.3%
nausea 50%
anaemia 33.3%
NCT04420598 · Phase 2 · registry result, not featured evidence
nausea 57.1%
anaemia 42.9%
fatigue 42.9%
NCT04420598 · Phase 2 · registry result, not featured evidence

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline

Trastuzumab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT04494425 · Phase 3 · active, not recruiting

The trial was large and randomized, with an active chemotherapy comparator and a hard clinical primary endpoint of progression-free survival, which was met: median PFS was 13.2 versus 8.1 months, with HR 0.62 and p<0.0001. However, treatment assignment was not blinded, so despite the strong randomized result this is considered moderate evidence rather than strong evidence.

Next expected readout: November 2026 · NCT06048718 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) (met)

Result source: NCT04494425

Trastuzumab pamirtecan

Developed by BioNTech under a licence from DualityBio Inc.

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2029 · NCT06827236 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointTrastuzumab DeruxtecanTrastuzumab pamirtecan
PFS, median—Trial running · NCT04494425—Trial running · NCT06018337
OS, median—Trial running · NCT04494425—Trial running · NCT06018337
ORR—Trial running · NCT04494425—Trial running · NCT06018337
Clinical benefit rate—Trial running · NCT04494425—Trial running · NCT06018337

PFS, median

Trastuzumab Deruxtecan
—Trial running · NCT04494425
Trastuzumab pamirtecan
—Trial running · NCT06018337

OS, median

Trastuzumab Deruxtecan
—Trial running · NCT04494425
Trastuzumab pamirtecan
—Trial running · NCT06018337

ORR

Trastuzumab Deruxtecan
—Trial running · NCT04494425
Trastuzumab pamirtecan
—Trial running · NCT06018337

Clinical benefit rate

Trastuzumab Deruxtecan
—Trial running · NCT04494425
Trastuzumab pamirtecan
—Trial running · NCT06018337
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Trastuzumab pamirtecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Trastuzumab Deruxtecan
Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) NCT04494425 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1) NCT03734029 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab Deruxtecan's landscape · Trastuzumab pamirtecan's landscape